Skip to main content
Erschienen in: Drug Safety 4/2015

01.04.2015 | Original Research Article

Assessment of a New Instrument for Detecting Preventable Adverse Drug Reactions

verfasst von: Raja Benkirane, Rachida Soulaymani-Bencheikh, Asmae Khattabi, Ghita Benabdallah, Loubna Alj, Houda Sefiani, Khedidja Hedna, Lahcen Ouammi, Sten Olsson, Shanti N. Pal

Erschienen in: Drug Safety | Ausgabe 4/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

Pharmacovigilance centres (PVCs) in the World Health Organization (WHO) Programme for International Drug Monitoring have demonstrated their ability to detect preventable adverse drug reactions (ADRs) in their databases. In this field, there is no gold-standard method for detecting medication errors and evaluating ADR preventability. Therefore, we developed, from existing tools, a preventability assessment method: the ‘P Method’ (PM).

Objective

To present the PM and to evaluate its inter-rater reliability.

Methods

The PM includes 20 explicit criteria for assessing ADR preventability. This approach is based on identification of any potentially preventable risk factor that increases the likelihood of ADR occurrence. The outcome of the preventability assessment results in one of three possible scores: ‘preventable’, ‘non-preventable’ or ‘not assessable’. The PM was tested in a multicentre study involving nine national PVCs. Two experienced reviewers at each participating PVC independently analysed the preventability of 183 ADRs, applying the PM.

Results

The overall agreement between all reviewers for assessment of ADR preventability was ‘fair’, with a kappa value of 0.27 [95 % confidence interval (CI) 0.21–0.40]. The level of agreement between reviewer pairs ranged from ‘slight’, with a kappa value of 0.12 (95 % CI −0.03 to 0.27), to ‘substantial’, with a kappa value of 0.69 (95 % CI 0.48–0.89).

Conclusion

The analysis of the agreements and disagreements between reviewers highlighted where improvements might be made. Given that no standard assessment tool exists in the WHO Programme, the transparency of the assessment process in this method provides a substantial basis for further development and for support in signalling possible preventability.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Alj L, Touzani MDW, Benkirane R, Edwards IR, Soulaymani R. Detecting medication errors in pharmacovigilance database: capacities and limits. Int J Risk Saf Med. 2007;19(4):187–94. Alj L, Touzani MDW, Benkirane R, Edwards IR, Soulaymani R. Detecting medication errors in pharmacovigilance database: capacities and limits. Int J Risk Saf Med. 2007;19(4):187–94.
2.
Zurück zum Zitat Kunac DL, Tatley MV. Detecting medication errors in the New Zealand pharmacovigilance database: a retrospective analysis. Drug Saf. 2011;34(1):59–71.CrossRefPubMed Kunac DL, Tatley MV. Detecting medication errors in the New Zealand pharmacovigilance database: a retrospective analysis. Drug Saf. 2011;34(1):59–71.CrossRefPubMed
3.
Zurück zum Zitat Caduff-Janosa P. Medication errors in Switzerland: an analysis of the spontaneous adverse reactions reports received at the Swissmedic Pharmacovigilance Centre. Drug Saf. 2004;27:831–977.CrossRef Caduff-Janosa P. Medication errors in Switzerland: an analysis of the spontaneous adverse reactions reports received at the Swissmedic Pharmacovigilance Centre. Drug Saf. 2004;27:831–977.CrossRef
4.
5.
Zurück zum Zitat Olivier P, Boulbés O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf. 2002;25(14):1035–44.CrossRefPubMed Olivier P, Boulbés O, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Assessing the feasibility of using an adverse drug reaction preventability scale in clinical practice: a study in a French emergency department. Drug Saf. 2002;25(14):1035–44.CrossRefPubMed
6.
Zurück zum Zitat Desai RJ, Williams CE, Greene SB, Pierson S, Caprio AJ, Hansen RA. Analgesic medication errors in North Carolina nursing homes. J Pain Palliat Care Pharmacother. 2013;27(2):125–31.CrossRefPubMed Desai RJ, Williams CE, Greene SB, Pierson S, Caprio AJ, Hansen RA. Analgesic medication errors in North Carolina nursing homes. J Pain Palliat Care Pharmacother. 2013;27(2):125–31.CrossRefPubMed
7.
Zurück zum Zitat Rajanayagam J, Bishop JR, Lewindon PJ, Evans HM. Paracetamol-associated acute liver failure in Australian and New Zealand children: high rate of medication errors. Arch Dis Child. doi:10.1136/archdischild-2013-304902. (Epub 2014 Sep 16). Rajanayagam J, Bishop JR, Lewindon PJ, Evans HM. Paracetamol-associated acute liver failure in Australian and New Zealand children: high rate of medication errors. Arch Dis Child. doi:10.​1136/​archdischild-2013-304902. (Epub 2014 Sep 16).
8.
Zurück zum Zitat Ferner RE, Aronson JK. Preventability of drug-related harms—part I: a systematic review. Drug Saf. 2010;33(11):985–94.CrossRefPubMed Ferner RE, Aronson JK. Preventability of drug-related harms—part I: a systematic review. Drug Saf. 2010;33(11):985–94.CrossRefPubMed
9.
Zurück zum Zitat Aronson JK, Ferner RE. Preventability of drug-related harms—part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf. 2010;33(11):995–1002.CrossRefPubMed Aronson JK, Ferner RE. Preventability of drug-related harms—part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf. 2010;33(11):995–1002.CrossRefPubMed
11.
Zurück zum Zitat Benabdallah G, Benkirane R, Khattabi A, Edwards IR, Soulaymani Bencheikh R. The involvement of pharmacovigilance centres in medication errors detection: a questionnaire-based analysis. Int J Risk Saf Med. 2011;23(1):17–29.PubMed Benabdallah G, Benkirane R, Khattabi A, Edwards IR, Soulaymani Bencheikh R. The involvement of pharmacovigilance centres in medication errors detection: a questionnaire-based analysis. Int J Risk Saf Med. 2011;23(1):17–29.PubMed
13.
Zurück zum Zitat Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care. 2004;13:306–14.CrossRefPubMedCentralPubMed Morimoto T, Gandhi TK, Seger AC, Hsieh TC, Bates DW. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care. 2004;13:306–14.CrossRefPubMedCentralPubMed
17.
Zurück zum Zitat Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.CrossRefPubMed Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–74.CrossRefPubMed
18.
Zurück zum Zitat Kunac DL, Reith DM, Kennedy J, Austin NC, Williams SM. Inter- and intra-rater reliability for classification of medication related events in paediatric inpatients. Qual Saf Health Care. 2006;15:196–201.CrossRefPubMedCentralPubMed Kunac DL, Reith DM, Kennedy J, Austin NC, Williams SM. Inter- and intra-rater reliability for classification of medication related events in paediatric inpatients. Qual Saf Health Care. 2006;15:196–201.CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMed Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm. 1992;27:538.PubMed
20.
Zurück zum Zitat Imbs JL, Pletan Y, Spriet A, et al. Evaluation de la iatrogénèse médicamenteuse évitable: méthodologie. Therapie. 1998;53:365–70.PubMed Imbs JL, Pletan Y, Spriet A, et al. Evaluation de la iatrogénèse médicamenteuse évitable: méthodologie. Therapie. 1998;53:365–70.PubMed
21.
Zurück zum Zitat Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012;35(2):105–26.CrossRefPubMed Hakkarainen KM, Andersson Sundell K, Petzold M, Hägg S. Methods for assessing the preventability of adverse drug events: a systematic review. Drug Saf. 2012;35(2):105–26.CrossRefPubMed
22.
Zurück zum Zitat Zegers M, de Bruijne MC, Wagner C, et al. The inter-rater agreement of retrospective assessments of adverse events does not improve with two reviewers per patient record. J Clin Epidemiol. 2010;63(1):94–102.CrossRefPubMed Zegers M, de Bruijne MC, Wagner C, et al. The inter-rater agreement of retrospective assessments of adverse events does not improve with two reviewers per patient record. J Clin Epidemiol. 2010;63(1):94–102.CrossRefPubMed
24.
Zurück zum Zitat Lip GY, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13:723–46.CrossRefPubMed Lip GY, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Europace. 2011;13:723–46.CrossRefPubMed
25.
Zurück zum Zitat Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869–74.CrossRefPubMed Ibanez L, Vidal X, Ballarin E, Laporte JR. Population-based drug-induced agranulocytosis. Arch Intern Med. 2005;165(8):869–74.CrossRefPubMed
26.
Zurück zum Zitat Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol. 1998;51(12):1357–65.CrossRefPubMed Andrade SE, Martinez C, Walker AM. Comparative safety evaluation of non-narcotic analgesics. J Clin Epidemiol. 1998;51(12):1357–65.CrossRefPubMed
Metadaten
Titel
Assessment of a New Instrument for Detecting Preventable Adverse Drug Reactions
verfasst von
Raja Benkirane
Rachida Soulaymani-Bencheikh
Asmae Khattabi
Ghita Benabdallah
Loubna Alj
Houda Sefiani
Khedidja Hedna
Lahcen Ouammi
Sten Olsson
Shanti N. Pal
Publikationsdatum
01.04.2015
Verlag
Springer International Publishing
Erschienen in
Drug Safety / Ausgabe 4/2015
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI
https://doi.org/10.1007/s40264-014-0257-5

Weitere Artikel der Ausgabe 4/2015

Drug Safety 4/2015 Zur Ausgabe